Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts

被引：1
|
作者：
George, B. [1 ,2 ]
Kelly, K. [3 ]
Ko, A. [4 ]
Soliman, H. [5 ]
Trunova, N. [6 ]
Wainberg, Z. [7 ]
Waterhouse, D. [8 ]
O'Dwyer, P. [9 ]
Hochster, H. [10 ]
机构：
[1] Froedtert, Div Hematol & Oncol, Milwaukee, WI USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Univ Calif Davis, Ctr Comprehens Canc, Internal Med, Sacramento, CA USA
[4] Celgene Corp, Biostats, Summit, NJ USA
[5] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA
[6] Celgene Corp, Med Affairs, Summit, NJ USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med, Los Angeles, CA 90095 USA
[8] Oncol Hematol Care, Med Oncol, Cincinnati, OH USA
[9] Univ Penn, Abramson Canc Ctr, Med, Philadelphia, PA 19104 USA
[10] Yale Canc Ctr, Med Oncol, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw378.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1059P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hirsh, V.
    Owen, S. P.
    Ko, A.
    Renschler, M.
    Socinski, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S21 - S21
  • [22] nab-Paclitaxel plus Carboplatin in Advanced Non-Small Cell Lung Cancer NSCLC: Dose Modification Analysis
    Postmus, Pieter E.
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Li, Li
    Ong, Teng Jin
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S658 - S658
  • [23] ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Langer, Corey J.
    Anderson, Eric C.
    Jotte, Robert M.
    Goldman, Jonathan Wade
    Haggstrom, Daniel Ernest
    Socoteanu, Matei Paul
    Smith, David A.
    Dakhil, Christopher
    Konduri, Kartik
    Kim, Edward S.
    Ong, Teng Jin
    Sanford, Alexandra
    Amiri, Katayoun
    Weiss, Jared
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
    Von Hoff, D. D.
    Ramanathan, R.
    Borad, M.
    Laheru, D.
    Smith, L.
    Wood, T.
    Korn, R.
    Desai, N.
    Iglesias, J.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] A Phase I Trial of Weekly Nab-paclitaxel Plus Carboplatin With Thoracic Radiotherapy for Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Sakai, Mizu
    Anabuki, Kazuki
    Takamatsu, Kazufumi
    Mukaida, Kenichi
    Kobayashi, Kana
    Yamagami, Takuji
    Yokoyama, Akihito
    IN VIVO, 2024, 38 (01): : 259 - 263
  • [26] Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
    Tabah, Ashley
    Huggar, David
    Kish, Jonathan
    Bapat, Bela
    Liassou, Djibril
    Gajra, Ajeet
    Miller, Talia
    Copher, Ronda
    Patel, Manali, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga Olanrele
    Bedoya, Ivan Dario
    Mierzwa, Michelle Lynn
    Torregroza, Maria Patricia
    Dwivedi, Alok Kumar
    Wang, Jiang
    Smith, Milton T.
    Schmulewitz, Nathan
    Kucera, Stephen
    Choe, Kyuran Ann
    Ristagno, Ross
    Rudich, Steven
    Sussman, Jeffrey J.
    Ahmad, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hirsh, V.
    Page, R. D.
    Ko, A.
    Renshler, M.
    Socinski, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S43 - S43
  • [29] Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)
    Lowery, Maeve Aine
    Harding, James J.
    Yu, Kenneth H.
    Kelsen, David Paul
    Bomalaski, John S.
    Glassman, Danielle C.
    Covington, Christina M.
    Brenner, Robin
    Hollywood, Ellen
    Barba, Adalberto
    Johnston, Amanda
    Liu, Kay Chia-Wei
    Capanu, Marinela
    Abou-Alfa, Ghassan K.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [30] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Taniguchi, Yoshihiko
    Katayama, Kanako
    Minomo, Shojiro
    Nakao, Keiko
    Takeuchi, Naoko
    Matsuda, Yoshinobu
    Naito, Yujiro
    Shiroyama, Takayuki
    Okamoto, Norio
    Okishio, Kyoichi
    Kumagai, Toru
    Atagi, Shinji
    Imamura, Fumio
    Hirashima, Tomonori
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1106 - 1112
12345